Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Recommendation of “Buy” by Brokerages

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has been given a consensus recommendation of “Buy” by the seven brokerages that are presently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $31.14.

A number of research analysts recently commented on the company. Truist Financial increased their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, November 11th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Citigroup increased their price objective on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Stephens started coverage on Catalyst Pharmaceuticals in a research report on Monday. They set an “overweight” rating and a $35.00 target price on the stock.

Insider Activity

In other news, Director David S. Tierney sold 15,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the transaction, the director now owns 348,874 shares in the company, valued at approximately $7,012,367.40. The trade was a 4.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 11.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Vestcor Inc raised its stake in shares of Catalyst Pharmaceuticals by 18.4% in the third quarter. Vestcor Inc now owns 60,431 shares of the biopharmaceutical company’s stock valued at $1,201,000 after acquiring an additional 9,379 shares during the last quarter. Barclays PLC raised its stake in shares of Catalyst Pharmaceuticals by 129.4% in the third quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company’s stock valued at $4,939,000 after acquiring an additional 140,129 shares during the last quarter. XTX Topco Ltd raised its stake in shares of Catalyst Pharmaceuticals by 73.3% in the third quarter. XTX Topco Ltd now owns 19,294 shares of the biopharmaceutical company’s stock valued at $384,000 after acquiring an additional 8,160 shares during the last quarter. iSAM Funds UK Ltd bought a new position in Catalyst Pharmaceuticals in the 3rd quarter worth approximately $216,000. Finally, Jane Street Group LLC lifted its holdings in Catalyst Pharmaceuticals by 245.4% during the 3rd quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock worth $7,990,000 after buying an additional 285,564 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX opened at $20.82 on Tuesday. Catalyst Pharmaceuticals has a 1-year low of $13.00 and a 1-year high of $24.27. The business has a 50-day moving average of $20.99 and a 200-day moving average of $18.37. The company has a market capitalization of $2.48 billion, a price-to-earnings ratio of 17.64, a PEG ratio of 3.17 and a beta of 0.75.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.